PALB2 and pachyonychia congenita: Based on this promising outcome, a randomized phase II trial of GEM/CDDP with or without veliparib is being performed for locally advanced/metastatic PC cases with BRCA1, BRCA2 or PALB2 mutation (NCT01585805).